The Company Outsmarting Big Pharma in Africa
Harvard Business Review
AUGUST 17, 2012
billion in the year ended March 2012, up close to ten times since 2000. To access these markets profitably, Cipla offers a broad portfolio of products, so that it can achieve economies of scale in marketing and distribution, and carefully monitors overheads (its SG&A is 20% versus the traditional big pharma 30%).
Let's personalize your content